Third German no for Eylea leaves Bayer vulnerable
This article was originally published in Scrip
Executive Summary
For the third time, Germany's reimbursement authority IQWiG has concluded that Bayer's Eylea (aflibercept) has no added benefit over its rival, Novartis's Lucentis (ranibizumab), this time for diabetic macular edema (DME). The decision will likely prevent Bayer from being able to command a premium price for Eylea in Germany.